{"authors": [["Williamson", "Douglas S", "DS", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Smith", "Garrick P", "GP", "H. Lundbeck A/S , Ottiliavej 9, 2500 Valby, Denmark."], ["Acheson-Dossang", "Pamela", "P", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Bedford", "Simon T", "ST", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Chell", "Victoria", "V", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Chen", "I-Jen", "IJ", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Daechsel", "Justus C A", "JCA", "H. Lundbeck A/S , Ottiliavej 9, 2500 Valby, Denmark."], ["Daniels", "Zoe", "Z", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["David", "Laurent", "L", "H. Lundbeck A/S , Ottiliavej 9, 2500 Valby, Denmark."], ["Dokurno", "Pawel", "P", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Hentzer", "Morten", "M", "H. Lundbeck A/S , Ottiliavej 9, 2500 Valby, Denmark."], ["Herzig", "Martin C", "MC", "H. Lundbeck A/S , Ottiliavej 9, 2500 Valby, Denmark."], ["Hubbard", "Roderick E", "RE", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Moore", "Jonathan D", "JD", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Murray", "James B", "JB", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Newland", "Samantha", "S", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Ray", "Stuart C", "SC", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Shaw", "Terry", "T", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Surgenor", "Allan E", "AE", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Terry", "Lindsey", "L", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Thirstrup", "Kenneth", "K", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Wang", "Yikang", "Y", "Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom."], ["Christensen", "Kenneth V", "KV", "H. Lundbeck A/S , Ottiliavej 9, 2500 Valby, Denmark."]], "date": "2017-10-27", "id": "29023112", "text": "Mutations in leucine-rich repeat kinase 2 (LRRK2), such as G2019S, are associated with an increased risk of developing Parkinson's disease. Surrogates for the LRRK2 kinase domain based on checkpoint kinase 1 (CHK1) mutants were designed, expressed in insect cells infected with baculovirus, purified, and crystallized. X-ray structures of the surrogates complexed with known LRRK2 inhibitors rationalized compound potency and selectivity. The CHK1 10-point mutant was preferred, following assessment of surrogate binding affinity with LRRK2 inhibitors. Fragment hit-derived arylpyrrolo[2,3-b]pyridine LRRK2 inhibitors underwent structure-guided optimization using this crystallographic surrogate. LRRK2-pSer935 HEK293 IC50 data for 22 were consistent with binding to Ala2016 in LRRK2 (equivalent to Ala147 in CHK1 10-point mutant structure). Compound 22 was shown to be potent, moderately selective, orally available, and brain-penetrant in wild-type mice, and confirmation of target engagement was demonstrated, with LRRK2-pSer935 IC50 values for 22 in mouse brain and kidney being 1.3 and 5 nM, respectively.", "doi": "10.1021/acs.jmedchem.7b01186", "title": "Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).", "journal": ["Journal of medicinal chemistry", "J. Med. Chem."]}